Skip to main content

Advertisement

SpringerLink
Log in

Sunitinib monotherapy in a patient with primary breast cancer

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for use in patients with advanced renal cell carcinoma (RCC). However, despite its preclinical biological effect on breast cancer, it is yet to be proven effective for clinical use in patients with breast cancer. The present report describes a case of a 69-year-old woman with advanced clear-cell RCC and a luminal B subtype invasive ductal carcinoma of the right breast that showed a partial response to monotherapy with sunitinib. This is the first report of the effect of sunitinib monotherapy in a patient with early-stage breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Matsuda A, Matsuda T, Shibata A et al (2013) Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 43(3):328–336

    Article  PubMed  Google Scholar 

  2. Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810–1816

    Article  PubMed  CAS  Google Scholar 

  3. Bergh J, Bondarenko IM, Lichinitser MR et al (2010) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30:921–929

    Article  CAS  Google Scholar 

  4. Crown J, Dieras V, Straroslawska E et al (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 28:18s (suppl; abstr LBA1011)

    Google Scholar 

  5. Barrios C, Liu MC, Lee S et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121–131

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Robert NJ, Saleh MN, Paul D et al (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:82–92

    Article  PubMed  CAS  Google Scholar 

  7. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    PubMed  CAS  Google Scholar 

  8. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971–979

    Article  PubMed  CAS  Google Scholar 

  9. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  10. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  11. The ATAC Trialists’ Group, Forbes JF, Cuzick J et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 9:45–53

    Article  PubMed  CAS  Google Scholar 

  12. Ferrara N, Gerber HP, LeCouter J (2003) The biological properties of VEGF and its receptors. Nat Med 9:669–676

    Article  PubMed  CAS  Google Scholar 

  13. Toi M, Inada K, Hoshina S et al (1995) Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1:961–964

    PubMed  CAS  Google Scholar 

  14. Gasparini G, Bonokli E, Gatti C et al (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89(2):139–147

    Article  PubMed  CAS  Google Scholar 

  15. Young E, Miele L, Tucker KB et al (2010) SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Cancer Biol Ther 10:703–711

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Miller K, Estes M, Perkins S et al (2009) An exploratory study of the biological activity of sunitinib as a component of neoadjuvant therapy for breast cancer. Cancer Res. 69:24 Suppl (abstract nr 202)

    Google Scholar 

  17. Keyvanjah K, DePrimo SE, Harmon CS et al (2012) Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. J Transl Med 10:165. doi:10.1186/1479-5876-10-165

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  18. Brown LF, Berse B, Jackman RW et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86–91

    Article  PubMed  CAS  Google Scholar 

  19. Liu Y, Tamimi RM, Collins LC et al (2011) The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study. Breast Cancer Res Treat 129:175–184

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Departments of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-0021, Japan

    Hitomi Sumiyoshi, Tomoyuki Aruga, Hiromi Miyamoto, Junko Ishiguro, Yayoi Honda, Takashi Shigekawa, Dai Kitagawa, Kazumi Horiguchi, Toshinari Yamashita & Katsumasa Kuroi

  2. Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-0021, Japan

    Shinichiro Horiguchi

Authors
  1. Hitomi Sumiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyuki Aruga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiromi Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junko Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yayoi Honda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Shigekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dai Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazumi Horiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshinari Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shinichiro Horiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Katsumasa Kuroi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hitomi Sumiyoshi or Tomoyuki Aruga.

About this article

Cite this article

Sumiyoshi, H., Aruga, T., Miyamoto, H. et al. Sunitinib monotherapy in a patient with primary breast cancer. Int Canc Conf J 3, 91–95 (2014). https://doi.org/10.1007/s13691-013-0122-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-013-0122-x

Keywords

Search

Navigation